OncoTracker Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $150K

OncoTracker General Information

Description

Provider of medical diagnostics services intended to detect and cure cancer and other diseases. The company's assay is based on measuring B-cell maturation antigen (BCMA) and helps in monitoring and predicting outcomes for multiple myeloma and chronic lymphocytic leukemia patients, enabling doctors to rapidly and accurately assess changes in a patient's cancer and further predict treatment efficacy.

Contact Information

Website
www.oncotracker.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Laboratory Services (Healthcare)
Biotechnology
Primary Office
  • 9201 Sunset Boulevard
  • Suite 307
  • West Hollywood, CA 90069
  • United States
+1 (424) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OncoTracker Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC 13-Feb-2020 $150K 00000 Completed Generating Revenue
2. Later Stage VC 13-Mar-2019 0000 0000 Completed Generating Revenue
1. Seed Round 10-Nov-2016 $1.12M Completed Generating Revenue
To view OncoTracker’s complete valuation and funding history, request access »

OncoTracker Patents

  • 36

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 4

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

OncoTracker Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3873478-A2 Method of enhancing immune-based therapy Pending 31-Oct-2018 0000000000
EP-3873478-A4 Method of enhancing immune-based therapy Pending 31-Oct-2018 0000000000 0
US-20220000872-A1 Method of enhancing immune-based therapy Pending 31-Oct-2018 000000000000
US-20200264184-A1 Diagnostic, prognostic, and monitoring methods for solid tumor cancers Active 13-Jun-2017 000000000000
EP-3639028-A1 Diagnostic, prognostic, and monitoring methods for solid tumor cancers Pending 13-Jun-2017 C07K16/2878
To view OncoTracker’s complete patent history, request access »

OncoTracker Executive Team (6)

Name Title Board Seat Contact Info
Jessica Yataco Co-Chief Operating Officer
James Berenson MD Co-Founder, President, Co-Chief Executive Officer, Principal, Chief Scientific Officer & Board Member
James Kuo MD Co-Chief Executive Officer
Tom Gosney Co-Chief Operating Officer & Chief Financial Officer
Kelly Bryant Chief Commercial Officer
You’re viewing 5 of 6 executive team members. Get the full list »

OncoTracker Board Members (3)

Name Representing Role Since
James Berenson MD OncoTracker Co-Founder, President, Co-Chief Executive Officer, Principal, Chief Scientific Officer & Board Member 000 0000
Ron Rogers OncoTracker Board Member 000 0000
You’re viewing 2 of 3 board members. Get the full list »

OncoTracker Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial